Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Protocol: Mosunetuzumab subQ with Polatuzumab Vedotin for Rel/Reg Large B-Cell Lymphoma
The SUNMO trial demonstrated that the combination of mosunetuzumab and polatuzumab vedotin improved overall response rate and progression-free survival compared to R-GemOx in trans
New Protocol: Fuzuloparib with Apatinib for BRCA1/2 Mutated Breast Cancer
The interim analysis of the FABULOUS study showed that fuzuloparib combined with apatinib significantly improved progression-free survival compared with chemotherapy in patients wi
New Reference: Adjuvant Capecitabine for Triple-Negative Breast Cancer
The SYSUCC-001 trial showed that metronomic capecitabine as extended adjuvant therapy significantly improves 10-year disease-free survival in early triple-negative breast cancer. A
New Reference: Amivantamab – Lazertinib for NSCLC with Atypical EGFR Mutations
In the CHRYSALIS-2 study, amivantamab plus lazertinib showed a 52% overall response rate in patients with atypical EGFR-mutated advanced NSCLC. The combination treatment led to a m
New Drug: Sevabertinib in Advanced HER2-Mutant NSCLC
Sevabertinib showed significant activity in patients with HER2-mutant NSCLC, achieving high response rates across different cohorts. The drug demonstrated a favorable response even
New Drug: Sacituzumab Tirumotecan for EGFR-Mutated Advanced NSCLC
Sacituzumab tirumotecan significantly improved progression-free survival and overall survival in patients with EGFR-mutated NSCLC resistant to previous EGFR-TKI therapy compared to
New Reference: Rucaparib for Maintenance in Advanced Ovarian Cancer
The ATHENA-MONO study demonstrated significant improvement in progression-free survival with rucaparib as maintenance therapy for newly diagnosed advanced ovarian cancer. The hazar
New Indication: Trastuzumab Deruxtecan with Pertuzumab for First-Line Metastatic Her2-Positive Breast Cancer
Trastuzumab deruxtecan plus pertuzumab demonstrated a significantly lower risk of progression or death compared to the THP regimen as a first-line treatment for HER2-positive metas
New Indication: Neoadjuvant Trastuzumab Deruxtecan For High-Risk her2-Positive Breast Cancer
This phase 3 trial showed that T-DXd-THP significantly improved the pathological complete response rate compared with ddAC-THP in high-risk HER2-positive early breast cancer, with
